Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 1996 Aug;7(6):640-2.

Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients.

Author information

  • 1Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.

Abstract

BACKGROUND:

To evaluate the activity of CAP regimen in advanced salivary gland carcinomas.

PATIENTS AND METHODS:

Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included.

RESULTS:

Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months.

CONCLUSIONS:

In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.

PMID:
8879381
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk